$ULBI
ULTRALIFE CORP Stock $ulbi

$ulbi Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924013121 Filed on April 25, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$42.98M	$41.93M
YoY Change	0.68%	31.37%
Cost Of Revenue	$31.42M	$30.46M
YoY Change	-2.13%	24.42%
Gross Profit	$11.56M	$11.47M
YoY Change	9.21%	54.25%
Gross Profit Margin	26.9%	27.36%
Selling, General & Admin	$5.649M	$5.651M
YoY Change	14.31%	5.08%
% of Gross Profit	48.85%	49.27%
Research & Development	$1.997M	$1.756M
YoY Change	13.85%	-13.58%
% of Gross Profit	17.27%	15.31%
Depreciation & Amortization	$789.0K	$740.0K
YoY Change	-20.06%	-2.89%
% of Gross Profit	6.82%	6.45%
Operating Expenses	$7.646M	$7.407M
YoY Change	10.44%	-0.04%
Operating Profit	$3.917M	$4.063M
YoY Change	6.88%	15526.92%
Interest Expense	-$418.0K	-$520.0K
YoY Change	-5.0%	22.64%
% of Operating Profit	-10.67%	-12.8%
Other Income/Expense, Net	-$71.00K	-$456.0K
YoY Change	-104.74%	-7.69%
Pretax Income	$3.846M	$3.607M
YoY Change	-18.57%	-870.73%
Income Tax	$853.0K	$703.0K
% Of Pretax Income	22.18%	19.49%
Net Earnings	$2.969M	$2.891M
YoY Change	-11.11%	-935.55%
Net Earnings / Revenue	6.91%	6.9%
Basic Earnings Per Share	$0.21	$0.21
Diluted Earnings Per Share	$0.21	$0.21
COMMON SHARES
Basic Shares Outstanding	16.47M	16.45M
Diluted Shares Outstanding	16.83M	16.52M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.690M	$10.10M
YoY Change	-18.43%	80.18%
Cash & Equivalents	$6.690M	$10.10M
Short-Term Investments
Other Short-Term Assets	$4.650M	$5.104M
YoY Change	-5.7%	28.47%
Inventory	$41.39M	$43.82M
Prepaid Expenses
Receivables	$31.06M	$35.28M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$83.79M	$94.30M
YoY Change	-4.6%	15.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.28M	$20.67M
YoY Change	-12.99%	-3.47%
Goodwill	$37.51M	$37.50M
YoY Change	0.02%	-0.05%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.505M	$3.340M
YoY Change	-59.79%	54.63%
Total Long-Term Assets	$86.03M	$86.25M
YoY Change	-1.75%	-3.96%
TOTAL ASSETS
Total Short-Term Assets	$83.79M	$94.30M
Total Long-Term Assets	$86.03M	$86.25M
Total Assets	$169.8M	$180.6M
YoY Change	-3.18%	5.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.691M	$13.32M
YoY Change	-47.73%	-29.88%
Accrued Expenses	$8.882M	$8.061M
YoY Change	2.54%	-1.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.000M	$2.000M
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$20.57M	$23.38M
YoY Change	-29.55%	-19.94%
LONG-TERM LIABILITIES
Long-Term Debt	$9.978M	$23.14M
YoY Change	-55.93%	9.53%
Other Long-Term Liabilities	$4.279M	$3.415M
YoY Change	114.38%	73.44%
Total Long-Term Liabilities	$14.26M	$26.56M
YoY Change	-42.13%	14.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.57M	$23.38M
Total Long-Term Liabilities	$14.26M	$26.56M
Total Liabilities	$36.47M	$51.61M
YoY Change	-34.71%	-5.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$34.89M	-$37.86M
YoY Change	-22.38%	-21.6%
Common Stock	$2.106M	$2.089M
YoY Change	2.28%	1.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$133.2M	$128.8M
YoY Change
Total Liabilities & Shareholders Equity	$169.8M	$180.6M
YoY Change	-3.18%	5.49%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$2.969M	$2.891M
YoY Change	-11.11%	-935.55%
Depreciation, Depletion And Amortization	$789.0K	$740.0K
YoY Change	-20.06%	-2.89%
Cash From Operating Activities	$8.925M	-$81.00K
YoY Change	409.71%	-94.07%
INVESTING ACTIVITIES
Capital Expenditures	$360.0K	$372.0K
YoY Change	-30.23%	-25.15%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$360.0K	-$372.0K
YoY Change	-30.23%	-25.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-11.93M	$185.0K
YoY Change	-863.64%	-89.72%
NET CHANGE
Cash From Operating Activities	8.925M	-$81.00K
Cash From Investing Activities	-360.0K	-$372.0K
Cash From Financing Activities	-11.93M	$185.0K
Net Change In Cash	-3.363M	-$179.0K
YoY Change	-220.24%	65.74%
FREE CASH FLOW
Cash From Operating Activities	$8.925M	-$81.00K
Capital Expenditures	$360.0K	$372.0K
Free Cash Flow	$8.565M	-$453.0K
YoY Change	593.52%	-75.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	24480000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1756000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5651000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	7407000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4063000	usd
CY2024Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	520000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	64000	usd
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000875657
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2023Q1	ulbi	Dilutive Securities Included In Computation Of Earnings Per Share Amount DilutiveSecuritiesIncludedInComputationOfEarningsPerShareAmount	0
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5378000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	7410000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	26000	usd
CY2023Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	424000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-70000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-456000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-494000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3607000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-468000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	703000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-133000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	2904000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-335000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	11000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	2891000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-346000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-232000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	197000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2659000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-149000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16396000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16135000
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	122000
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16518000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16135000
CY2024Q1	us-gaap	Depreciation Depreciation	740000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	762000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	228000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	209000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	16000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	16000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	161000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	139000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-650000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	390000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3562000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3365000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1699000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6026000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1102000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-639000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-621000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	256000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-81000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1365000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	372000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	497000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-372000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-497000	usd
CY2024Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2300000	usd
CY2024Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	500000	usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	500000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	685000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	185000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1800000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-46000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-179000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-108000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10278000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5713000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10099000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5605000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	116403000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-335000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	138000	usd
CY2023Q1	ulbi	Adjustments To Additional Paid In Capital Sharebased Compensation Restricted Stock Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRestrictedStockRequisiteServicePeriodRecognition	1000	usd
CY2023Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	197000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	116404000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	125427000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	2904000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	156000	usd
CY2024Q1	ulbi	Adjustments To Additional Paid In Capital Sharebased Compensation Restricted Stock Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRestrictedStockRequisiteServicePeriodRecognition	5000	usd
CY2024Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-232000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	128945000	usd
CY2024Q1	ulbi	Dilutive Securities Included In Computation Of Earnings Per Share Amount DilutiveSecuritiesIncludedInComputationOfEarningsPerShareAmount	539358
CY2024Q1	ulbi	Dilutive Securities Included In Computation Of Earnings Per Share Amount Restricted Stock DilutiveSecuritiesIncludedInComputationOfEarningsPerShareAmountRestrictedStock	5229
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	122515
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10099000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10196000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	82000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10099000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10278000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	30168000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	29098000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3593000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3187000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10060000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9930000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	43821000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	42215000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	86990000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	87601000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	66320000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	66484000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20670000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21117000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	740000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	762000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	37571000	usd
CY2024Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-72000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	37499000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	28214000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13347000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14867000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	28247000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13140000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15107000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	228000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	209000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	161000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	139000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1250595
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.1
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3460
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.84
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	103839
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.6
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	86356
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.96
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1063860
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M19D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2258000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	964552
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.07
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y21D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1987000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	604537
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	7.5
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y11M1D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1018000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	685000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.195	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.284	pure
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	262000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	241000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	28000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	28000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	290000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	269000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	265000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	226000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045	pure
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	620000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	691000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	618000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	639000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	642000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	458000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3668000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	538000	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	547000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	323000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	141000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	84000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	49000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	21000	usd
CY2024Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	639000	usd
CY2023Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	386000	usd
CY2024Q1	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	1335000	usd
CY2023Q4	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	1407000	usd
CY2024Q1	us-gaap	Revenues Revenues	41927000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4063000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-456000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	703000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	2891000	usd
CY2023Q1	us-gaap	Revenues Revenues	31916000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	26000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-494000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-133000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	11000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-346000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	41927000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	31916000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	41927000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	31916000	usd

Files In Submission

Name	View Source	Status
0001437749-24-013121-index-headers.html	Edgar Link	pending
0001437749-24-013121-index.html	Edgar Link	pending
0001437749-24-013121.txt	Edgar Link	pending
0001437749-24-013121-xbrl.zip	Edgar Link	pending
ex_657176.htm	Edgar Link	pending
ex_657177.htm	Edgar Link	pending
ex_657178.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ulbi-20240331.xsd	Edgar Link	pending
ulbi20240331_10q.htm	Edgar Link	pending
ulbi-20240331_pre.xml	Edgar Link	unprocessable
ulbi20240331_10q_htm.xml	Edgar Link	completed
ulbi-20240331_cal.xml	Edgar Link	unprocessable
ulbi-20240331_lab.xml	Edgar Link	unprocessable
ulbi-20240331_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ULBI
ULTRALIFE CORP Stock $ulbi

2024 Q2 Form 10-Q Financial Statement

#000143774924013121 Filed on April 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ULBI ULTRALIFE CORP Stock $ulbi

2024 Q2 Form 10-Q Financial Statement

#000143774924013121 Filed on April 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ULBI
ULTRALIFE CORP Stock $ulbi